FDA approval introduces first-in-class, once-daily oral TYK2 inhibition for active psoriatic arthritis, expanding deucravacitinib beyond its 2022 plaque psoriasis indication. POETYK PsA-1 and PsA-2 ...
An Informational Analysis of TrimRx Compounded Semaglutide and Tirzepatide Programs, Telehealth Prescription Process, Published Pricing Disclosures, Pharmacy Partnerships and Patient Safety Informatio ...
A 2026 informational consumer research report examining FocusMax cognitive support marketing claims, ingredient-level research context, proprietary blend transparency, pricing disclosures, and verific ...
Moby summary of Amylyx Pharmaceuticals, Inc.'s Q4 2025 earnings call ...
Healthdirect, Australia's national virtual health service provider, has recently introduced a patient consultation summary ...
A guide to Medicare coverage for breast cancer diagnosis and treatment, including cost differences between Original Medicare ...
Moby summary of Altimmune, Inc.'s Q4 2025 earnings call ...
A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.
Good afternoon, and welcome to Cumberland Pharmaceuticals 2025 Financial Report and Company Update. This call is being recorded at the company's request and will be archived on its website for 1 year ...
Objective: To determine whether industry payments to cardiologists are associated with Medicare beneficiary spending, as financial incentives may influence clinical deci ...
KwikPen® for single-patient use available from Lilly at $449 across all doses through the Lilly Employer Connect platform, with reduced cost-share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results